Resultados de procura - Jake Shortt

P1678: INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION por Briony Shaw, Catriona Parker, Jake Shortt, Stephen Opat, Peter Poon

Ligazón do recurso

Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy por Thomas P. Toohey, Jake Shortt, Nevin John, Salmaan Al-Qureshi, Sanjeewa S. Wickremasinghe

Ligazón do recurso

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma por Matteo Costacurta, Stephin J Vervoort, Simon J Hogg, Benjamin P Martin, Ricky W Johnstone, Jake Shortt

Ligazón do recurso

Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse por Mark Waltham, Jonathan Wong, Galina Polekhina, Tessa Potezny, Pranav Dorwal, Daniella Brasacchio, Belinda Maher, Aditya Tedjaseputra, Gareth P. Gregory, Stephen Opat, Jake Shortt

Ligazón do recurso

Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough? por Mark A. Dawson, Sharon Avery, Zoe K. McQuilten, Michael J. Bailey, Jake Shortt, Mark N. Polizzotto, Erica M. Wood, Merrole F. Cole-Sinclair

Ligazón do recurso

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUB... por Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold Keer, Jason Taylor, Enrica Marchi

Ligazón do recurso

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS por Gareth P. Gregory, Michael Dickinson, Costas K. Yannakou, Jonathan Wong, Piers Blombery, Greg Corboy, Lev Kats, Tim M.E. Crozier, Beena Kumar, H. Miles Prince, Stephen S. Opat, Jake Shortt

Ligazón do recurso

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases por Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S. Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John V. Catalano, Sanjeev D. Chunilal, Anna Johnston, Stephen S. Opat, Jake Shortt

Ligazón do recurso

P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY por Won-Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalya Mikhaylova, Ana Marin-Niebla, Dejan Radeski, Vincent Ribrag, Eva Domingo Domènech, Ahmed Sawas, Karenza Alexis, Michael Emig, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz

Ligazón do recurso

P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANA... por Jake Shortt, Tatyana Feldman, Graham Collins, Jasmine Zain, Amit Khot, Jin Seok Kim, Franck Morschhauser, Tae Min Kim, Justine Roderick, Jeong Lim Yoon, Shringi Sharma, Jamal Saeh, Jiale Dai, Ruben Reyes, Richardp Olsson, Pier Luigi Zinzani

Ligazón do recurso

Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus por Baolong Pan, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle R. Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, Sam A. Greenall, Nadia Warner

Ligazón do recurso

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA por Danielle H. Oh, Xiao MA, Jackson He, Conor Kearney, Simon J. Hogg, Andrea Newbold, Peter Fraser, Ian G. Jennings, Daniella Brasacchio, Olivia Susanto, Chun Yew Fong, Mark A. Dawson, Emily Gruber, Lev Kats, Ricky W. Johnstone, Philip E. Thompson, Jake Shortt

Ligazón do recurso

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia por Lucy C. Fox, Katherine D. Cummins, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg

Ligazón do recurso

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial por Eliza A. Hawkes, Jodie B. Palmer, Richard Khor, Sze Ting Lee, Melinda Burgess, Soi C. Law, Maher K. Gandhi, Geoffrey Chong, Jake Shortt, Rakin Chowdhury, Fiona Swain, Leonid Churilov, Michael MacManus, Charmaine Smith, Fiona E. Scott, Arina Martynchyk, Allison Barraclough, Kate Manos, Andrew M. Scott, Colm Keane

Ligazón do recurso

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM... por Matteo Giovanni Della Porta, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui LI, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Jeevan K. Shetty, Sheida Hayati, Sadanand Vodala, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Guillermo Garcia-Manero

Ligazón do recurso

Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasia... por Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Li Mei Poon, Erin Paul, Matthew Ku, Mark Wong, Sylvia Ai, Ashley Beekman, Pietro R. Di Ciaccio, Michael Krigstein, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Shir‐Jing Ho, Tara Cochrane, Eliza A. Hawkes, Chan Y. Cheah, Stephen Opat, Gareth P. Gregory

Ligazón do recurso

How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials? por Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W. Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H. Wei, Australasian Leukaemia and Lymphoma Group (ALLG)

Ligazón do recurso